Headache education by leaflet distribution during COVID‐19 vaccination and school‐based on‐demand e‐learning: Itoigawa Geopark Headache Awareness Campaign

Abstract

Objective: We prospectively performed the Itoigawa Headache Awareness Campaign from August 2021 to June 2022, with two main interventions, and evaluated its effectiveness.Background: Headache is a common public health problem, but its burden could be reduced by raising awareness about headache and the appropriate use of acute and prophylactic medication. However, few studies on raising headache awareness in the general public have been reported. Methods:The target group was the general public aged 15-64. We performed two main interventions synergistically supported by other small interventions. Intervention 1 included leaflet distribution and a paper-based questionnaire about headache during COVID-19 vaccination, and intervention 2 included on-demand e-learning and online survey through schools. In these interventions, we emphasize the six important topics for the general public that were described in the Clinical Practice Guideline for Headache Disorders 2021. Each response among the two interventions' cohorts was collected on pre and post occasions. The awareness of the six topics before and after the campaign was evaluated. Results: We obtained 4016 valid responses from 6382 individuals who underwent vaccination in intervention 1 and 2577 from 594 students and 1983 parents in intervention 2; thus, 6593 of 20,458 (32.2%) of the overall working-age population in Itoigawa city experienced these interventions. The percentage of individuals' aware of the six topics significantly increased after the two main interventions ranging from 6.6% (39/594)-40.0% (1606/4016) to 64.1% (381/594)-92.6% (1836/1983) (p < 0.001, all). ME THODS Campaign procedureWe performed this headache awareness campaign prospectively

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine

“…It may be effective in elderly patients who cannot be operated on and in TN without neurovascular compression, in other words, with no identifiable cause on radiological imaging [16]. In the course of our migraine awareness activities [17] and epidemiological studies [18][19][20], we sometimes encounter TN patients who actually have migraine headaches, as described above. Further real-world data accumulation and prospective randomized-control trials for patients with both TN and migraine using 70 mg erenumab are expected.…”

Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross‐sectional study

“…4 More than a third (36.5%) of people who have migraine attacks hesitate to consult doctors, and 89.8% have never used prophylactic medications. 1 Therefore, raising awareness 4 and conducting research on the triggers and etiology of migraine headaches is needed.…”

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases

“…CGRP is a 37-amino-acid signaling neuropeptide and is involved in migraine and other trigeminal nerve-related or facial pain disorders. CGRP-mABs are now widely used as epidemiological studies are conducted [ 15 ], and patient interest in treatment increases [ 16 ]. Considering that CH can be complicated by migraine headaches [ 17 ], that CGRP may relate to both CH and migraine [ 18 , 19 , 20 ], that trigger factors, such as alcohol, and treatment response to triptans are clinically similar [ 21 ], and that migraine headaches are accompanied by autonomic symptoms [ 4 ], CH and migraine headaches may overlap in their mechanism.…”